DK1578738T3 - Escitalopram-hydrobromid og fremgangsmåde til fremstilling deraf - Google Patents
Escitalopram-hydrobromid og fremgangsmåde til fremstilling derafInfo
- Publication number
- DK1578738T3 DK1578738T3 DK03779759T DK03779759T DK1578738T3 DK 1578738 T3 DK1578738 T3 DK 1578738T3 DK 03779759 T DK03779759 T DK 03779759T DK 03779759 T DK03779759 T DK 03779759T DK 1578738 T3 DK1578738 T3 DK 1578738T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparation
- escitalopram hydrobromide
- escitalopram
- hydrobromide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200202005 | 2002-12-23 | ||
PCT/DK2003/000902 WO2004056791A1 (en) | 2002-12-23 | 2003-12-18 | Escitalopram hydrobromide and a method for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1578738T3 true DK1578738T3 (da) | 2008-06-30 |
Family
ID=32668635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03779759T DK1578738T3 (da) | 2002-12-23 | 2003-12-18 | Escitalopram-hydrobromid og fremgangsmåde til fremstilling deraf |
Country Status (33)
Country | Link |
---|---|
US (1) | US20040167209A1 (sr) |
EP (1) | EP1578738B1 (sr) |
JP (2) | JP4658613B2 (sr) |
KR (1) | KR20050086933A (sr) |
CN (1) | CN100349885C (sr) |
AR (1) | AR042652A1 (sr) |
AT (1) | ATE388947T1 (sr) |
AU (1) | AU2003287919B2 (sr) |
BR (1) | BR0317623A (sr) |
CA (1) | CA2511142A1 (sr) |
CY (1) | CY1107451T1 (sr) |
DE (1) | DE60319739T2 (sr) |
DK (1) | DK1578738T3 (sr) |
EA (1) | EA013116B1 (sr) |
EG (1) | EG24729A (sr) |
ES (1) | ES2298595T3 (sr) |
HK (1) | HK1087708A1 (sr) |
IL (1) | IL169125A0 (sr) |
IS (1) | IS2654B (sr) |
ME (1) | MEP5808A (sr) |
MX (1) | MXPA05005772A (sr) |
MY (1) | MY135468A (sr) |
NO (1) | NO20053595L (sr) |
NZ (1) | NZ540281A (sr) |
PE (1) | PE20040924A1 (sr) |
PL (1) | PL378275A1 (sr) |
PT (1) | PT1578738E (sr) |
RS (1) | RS51092B (sr) |
TW (1) | TW200501943A (sr) |
UA (1) | UA80170C2 (sr) |
UY (1) | UY28148A1 (sr) |
WO (1) | WO2004056791A1 (sr) |
ZA (1) | ZA200504109B (sr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050137255A1 (en) * | 2002-12-23 | 2005-06-23 | H. Lundbeck A/S | Crystalline escitalopram hydrobromide and methods for preparing the same |
WO2004056791A1 (en) * | 2002-12-23 | 2004-07-08 | H. Lundbeck A/S | Escitalopram hydrobromide and a method for the preparation thereof |
NZ549100A (en) * | 2004-03-05 | 2010-02-26 | Lundbeck & Co As H | Crystalline composition containing escitalopram oxalate |
US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
TWI347942B (en) | 2005-06-22 | 2011-09-01 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
AU2006304889A1 (en) * | 2005-10-14 | 2007-04-26 | H. Lundbeck A/S | Stable pharmaceutical formulations containing escitalopram and bupropion |
AU2006308635A1 (en) * | 2005-10-14 | 2007-05-10 | H. Lundbeck A/S | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
JP5501615B2 (ja) * | 2006-07-11 | 2014-05-28 | 田辺三菱製薬株式会社 | モルホリン化合物の塩 |
WO2008059514A2 (en) * | 2006-07-31 | 2008-05-22 | Cadila Healthcare Limited | Process for preparing escitalopram |
FR3006594A1 (fr) * | 2013-06-11 | 2014-12-12 | Sorin Crm Sas | Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire |
CN108976188B (zh) * | 2017-06-05 | 2022-12-06 | 上海奥博生物医药股份有限公司 | 一种艾司西酞普兰双羟萘酸盐新的制备方法 |
PL3694843T3 (pl) | 2017-10-09 | 2022-06-20 | Hasleton, Mark | Nowa sól i nowe stałe postacie escitalopramu |
EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US34712A (en) * | 1862-03-18 | James h | ||
GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
CN1129592C (zh) * | 1998-10-20 | 2003-12-03 | H·隆德贝克有限公司 | 制备西酞普兰的方法 |
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
PT1228056E (pt) * | 1999-10-25 | 2005-02-28 | Lundbeck & Co As H | Metodo de preparacao de citaloprame |
JP2002020379A (ja) * | 2000-05-02 | 2002-01-23 | Sumika Fine Chemicals Co Ltd | シタロプラム臭化水素酸塩の結晶およびその結晶化方法 |
US6977306B2 (en) * | 2000-05-02 | 2005-12-20 | Sumitomo Chemical Company, Limited | Citalopram hydrobromide crystal and method for crystallization thereof |
IS6021A (is) * | 2000-08-10 | 2001-10-20 | H. Lundbeck A/S | Lyfjasamsetningar sem innihalda sítalópram |
CA2430146C (en) * | 2000-12-04 | 2011-02-15 | Dr. Frische Gmbh | Method for the production of fatty acid esters |
MXPA03008777A (es) * | 2001-05-01 | 2004-02-12 | Lundbeck & Co As H | El uso de escitalopram enantiomericamente puro. |
AR034612A1 (es) | 2001-06-25 | 2004-03-03 | Lundbeck & Co As H | Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram |
WO2004056791A1 (en) * | 2002-12-23 | 2004-07-08 | H. Lundbeck A/S | Escitalopram hydrobromide and a method for the preparation thereof |
US20050174782A1 (en) * | 2003-03-25 | 2005-08-11 | Chapman Leonard T. | Flashlight |
-
2003
- 2003-12-18 WO PCT/DK2003/000902 patent/WO2004056791A1/en active IP Right Grant
- 2003-12-18 EP EP03779759A patent/EP1578738B1/en not_active Expired - Lifetime
- 2003-12-18 JP JP2004561083A patent/JP4658613B2/ja not_active Expired - Lifetime
- 2003-12-18 PL PL378275A patent/PL378275A1/pl not_active Application Discontinuation
- 2003-12-18 ES ES03779759T patent/ES2298595T3/es not_active Expired - Lifetime
- 2003-12-18 ME MEP-58/08A patent/MEP5808A/xx unknown
- 2003-12-18 PT PT03779759T patent/PT1578738E/pt unknown
- 2003-12-18 BR BR0317623-1A patent/BR0317623A/pt not_active IP Right Cessation
- 2003-12-18 CA CA002511142A patent/CA2511142A1/en not_active Abandoned
- 2003-12-18 AU AU2003287919A patent/AU2003287919B2/en not_active Ceased
- 2003-12-18 RS YUP-2005/0487A patent/RS51092B/sr unknown
- 2003-12-18 AT AT03779759T patent/ATE388947T1/de not_active IP Right Cessation
- 2003-12-18 DK DK03779759T patent/DK1578738T3/da active
- 2003-12-18 KR KR1020057011704A patent/KR20050086933A/ko not_active Application Discontinuation
- 2003-12-18 EA EA200501046A patent/EA013116B1/ru not_active IP Right Cessation
- 2003-12-18 CN CNB2003801063775A patent/CN100349885C/zh not_active Expired - Fee Related
- 2003-12-18 DE DE60319739T patent/DE60319739T2/de not_active Expired - Lifetime
- 2003-12-18 MX MXPA05005772A patent/MXPA05005772A/es active IP Right Grant
- 2003-12-18 UA UAA200506077A patent/UA80170C2/uk unknown
- 2003-12-18 NZ NZ540281A patent/NZ540281A/en not_active Application Discontinuation
- 2003-12-22 TW TW092136380A patent/TW200501943A/zh unknown
- 2003-12-22 MY MYPI20034949A patent/MY135468A/en unknown
- 2003-12-22 AR ARP030104777A patent/AR042652A1/es unknown
- 2003-12-23 US US10/746,913 patent/US20040167209A1/en not_active Abandoned
- 2003-12-23 UY UY28148A patent/UY28148A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 PE PE2004000013A patent/PE20040924A1/es not_active Application Discontinuation
-
2005
- 2005-05-17 IS IS7848A patent/IS2654B/is unknown
- 2005-05-20 ZA ZA200504109A patent/ZA200504109B/en unknown
- 2005-06-09 IL IL169125A patent/IL169125A0/en unknown
- 2005-06-22 EG EGNA2005000345 patent/EG24729A/xx active
- 2005-07-25 NO NO20053595A patent/NO20053595L/no not_active Application Discontinuation
-
2006
- 2006-07-18 HK HK06108012A patent/HK1087708A1/xx not_active IP Right Cessation
-
2008
- 2008-05-02 CY CY20081100470T patent/CY1107451T1/el unknown
-
2010
- 2010-10-20 JP JP2010235287A patent/JP2011037893A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2015010I1 (no) | Everolimus - se vedlegg til søknad | |
DK1206495T3 (da) | Kimære polypeptider, fremgangsmåde til frembringelse og anvendelser deraf | |
DK1180518T3 (da) | 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
NO20032220D0 (no) | Löfteverktöy II og fremgangsmåte for anvendelse av samme | |
NO20012158D0 (no) | Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav | |
BRPI0313238A2 (pt) | método | |
NO20035697D0 (no) | 5-HT-reseptor-ligander og anvendelser derav | |
NO20051397D0 (no) | Enkeltfase samlingsapparat og fremgangsmate | |
DK1511734T3 (da) | Forbindelser, præparater og fremgangsmåder | |
DK1354224T3 (da) | Sensorindretning, fremgangsmåde til dens fremstilling og anvendelse | |
DK1620551T3 (da) | Phospholipase og fremgangsmåde til fremstilling deraf | |
DK1381605T3 (da) | Mercaptoacetylamidderivater, en fremgangsmåde til deres fremstilling og deres anvendelse | |
IS2654B (is) | Essítalópram hýdróbrómíð og aðferð til framleiðslu þess | |
NO20051875D0 (no) | Kjoleror og fremgangsmate for bruk av dette | |
IS7798A (is) | Efnasambönd, lyfjablöndur og aðferðir | |
DK1261697T3 (da) | Kuldeaktiv beta-galactosidase, fremgangsmåde til fremstilling heraf og anvendelsen deraf | |
DK1518827T3 (da) | Krystalliseret IM-12-faststof og fremgangsmåde til fremstilling heraf | |
DK1601744T3 (da) | Forgasningsapparat og fremgangsmåde | |
DK1568280T3 (da) | Fremgangsmåde til fremstilling af fermenteret mælk og fermenteret mælk | |
DK1359593T3 (da) | SPM-sensor og fremgangsmåde til dens fremstilling | |
DK1639107T3 (da) | Forbedrede proteaser og fremgangsmåder til fremstilling deraf | |
NO20014376D0 (no) | Anordning, fremgangsmåte og anvendelse | |
DK1261625T3 (da) | Memnopeptider, en fremgangsmåde til deres fremstilling og deres anvendelse | |
DK1406895T3 (da) | Lactonformuleringer og fremgangsmåde til anvendelse deraf |